Cargando…

Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma

SIMPLE SUMMARY: FGFR4 is a receptor tyrosine kinase overexpressed in rhabdomyosarcoma (RMS) and mutationally activated in ~10% of fusion-negative (FN) cases. The goal of this study was to evaluate the preclinical efficacy of futibatinib, a novel FGFR-family inhibitor, in treating RMS. We demonstrate...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Jerry T., Cheuk, Adam, Isanogle, Kristine, Robinson, Christina, Zhang, Xiaohu, Ceribelli, Michele, Beck, Erin, Shinn, Paul, Klumpp-Thomas, Carleen, Wilson, Kelli M., McKnight, Crystal, Itkin, Zina, Sotome, Hiroshi, Hirai, Hiroshi, Calleja, Elizabeth, Wacheck, Volker, Gouker, Brad, Peer, Cody J., Corvalan, Natalia, Milewski, David, Kim, Yong Y., Figg, William D., Edmondson, Elijah F., Thomas, Craig J., Difilippantonio, Simone, Wei, Jun S., Khan, Javed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452847/ https://www.ncbi.nlm.nih.gov/pubmed/37627061 http://dx.doi.org/10.3390/cancers15164034

Ejemplares similares

Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma
por: Lamarca, A., et al.
Publicado: (2023)

Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors
por: Javle, Milind, et al.
Publicado: (2023)

Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer
por: Saridogan, Turcin, et al.
Publicado: (2023)

A phase I, open‐label, single‐dose study to evaluate the effect of hepatic impairment on the pharmacokinetics and safety of futibatinib
por: Gao, Ling, et al.
Publicado: (2023)

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study
por: Meric-Bernstam, Funda, et al.
Publicado: (2022)

Phase I, first-in-human study of futibatinib, a highly selective, irreversible FGFR1–4 inhibitor in patients with advanced solid tumors
por: Bahleda, R., et al.
Publicado: (2020)

mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer
por: Kumari, Anju, et al.
Publicado: (2023)

Phase I study of the irreversible fibroblast growth factor receptor 1–4 inhibitor futibatinib in Japanese patients with advanced solid tumors
por: Doi, Toshihiko, et al.
Publicado: (2022)

Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma
por: Tian, Meijie, et al.
Publicado: (2023)

Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma
por: Fiorito, Elisa, et al.
Publicado: (2022)

Molecular mechanisms of Guadecitabine induced FGFR4 down regulation in alveolar rhabdomyosarcomas
por: Darvishi, Emad, et al.
Publicado: (2020)

ATRT-11. DEVELOPMENT OF NOVEL PRECLINICAL MODELS AND THERAPEUTIC STRATEGIES FOR ETMR
por: Cocito, Carolina, et al.
Publicado: (2023)

A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry
por: Xu, Miao, et al.
Publicado: (2021)

A high throughput screening assay for inhibitors of SARS-CoV-2 pseudotyped particle entry
por: Xu, Miao, et al.
Publicado: (2022)

Targeting Wild-Type and Mutationally Activated FGFR4 in Rhabdomyosarcoma with the Inhibitor Ponatinib (AP24534)
por: Li, Samuel Q., et al.
Publicado: (2013)

Novel FGFR4-Targeting Single-Domain Antibodies for Multiple Targeted Therapies against Rhabdomyosarcoma
por: Alijaj, Nagjie, et al.
Publicado: (2020)

FGF7–FGFR2 autocrine signaling increases growth and chemoresistance of fusion‐positive rhabdomyosarcomas
por: Milton, Christopher I., et al.
Publicado: (2021)

A Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19
por: Shrimp, Jonathan H., et al.
Publicado: (2022)

High-throughput and targeted drug screens identify pharmacological candidates against MiT-translocation renal cell carcinoma
por: Lang, Martin, et al.
Publicado: (2023)

FGFR4-Targeted Chimeric Antigen Receptors Combined with Anti-Myeloid Polypharmacy Effectively Treat Orthotopic Rhabdomyosarcoma
por: Sullivan, Peter M., et al.
Publicado: (2022)

The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators
por: Gorshkov, Kirill, et al.
Publicado: (2020)

Targeting ACE2-RBD interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of an AlphaLISA proximity assay
por: Hanson, Quinlin M., et al.
Publicado: (2020)

Targeting ACE2–RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay
por: Hanson, Quinlin M., et al.
Publicado: (2020)

BSCI-17. YOUNG AGE PROMOTES BREAST CANCER METASTASIS TO THE BRAIN
por: Wu, Alex, et al.
Publicado: (2019)

Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection
por: Shamim, Khalida, et al.
Publicado: (2021)

CD276-CAR T cells and Dual-CAR T cells targeting CD276/FGFR4 promote rhabdomyosarcoma clearance in orthotopic mouse models
por: Timpanaro, Andrea, et al.
Publicado: (2023)

Caveolins in rhabdomyosarcoma
por: Rossi, Stefania, et al.
Publicado: (2011)

Relapsed Rhabdomyosarcoma
por: Heske, Christine M., et al.
Publicado: (2021)

mQC: A Heuristic Quality-Control Metric for High-Throughput Drug Combination Screening
por: Chen, Lu, et al.
Publicado: (2016)

Human Rhabdomyosarcoma Cell Lines for Rhabdomyosarcoma Research: Utility and Pitfalls
por: Hinson, Ashley R. P., et al.
Publicado: (2013)

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening
por: Zhu, Wei, et al.
Publicado: (2020)

Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening
por: Zhu, Wei, et al.
Publicado: (2020)

Growth charts in FGFR2- and FGFR3-related faciocraniosynostoses
por: Ea, Caroline, et al.
Publicado: (2022)

Resistance to Selective FGFR Inhibitors in FGFR-Driven Urothelial Cancer
por: Facchinetti, Francesco, et al.
Publicado: (2023)

Novel mutation detection of fibroblast growth factor receptor 1 (FGFR1) gene, FGFR2IIIa, FGFR2IIIb, FGFR2IIIc, FGFR3, FGFR4 gene for craniosynostosis: A prospective study in Asian Indian patient
por: Barik, Mayadhar, et al.
Publicado: (2015)

The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules
por: Gorshkov, Kirill, et al.
Publicado: (2020)

Meclozine Facilitates Proliferation and Differentiation of Chondrocytes by Attenuating Abnormally Activated FGFR3 Signaling in Achondroplasia
por: Matsushita, Masaki, et al.
Publicado: (2013)

Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2
por: Chen, Catherine Z., et al.
Publicado: (2020)

Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2
por: Chen, Catherine Z., et al.
Publicado: (2021)

Pure testicular rhabdomyosarcoma.
por: Alexander, F.
Publicado: (1968)

Cannot write session to /tmp/vufind_sessions/sess_4jjbug4l82742oihjuba1i9p2j